Case-Specific Health Care Professional Clinical Survey of Liberant Thrombectomy System

What this Trial Is About

This research aims to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant Thrombectomy System. The system is used to remove fresh, soft emboli or thrombi from vessels in the peripheral arterial and venous systems. The study focuses on patients with various conditions including venous embolism, arterial embolism and thrombosis, deep vein thrombosis, peripheral arterial disease, and acute limb ischemia. The study is an observational, multicenter survey where health care professionals document their individual experiences using the Liberant device according to approved labeling. Each case is recorded within 72 hours of device use to identify any procedural risks and evaluate device performance. At least 50 cases will be collected from a minimum of 10 different health care providers. There is no follow-up with patients after the initial data collection. Participants' involvement includes treatment with the Liberant device as part of routine care. Data collected includes rates of serious adverse events related to the device, technical success, and procedural success during the index procedure. Individual case reports are aggregated by a third-party vendor for analysis. The study does not require additional patient visits or long-term monitoring and is planned to conclude by October 2026.

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System